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Abstract
Centrally administered insulin-like growth factor (IGF)-I has anti-depressant activity in several rodent models,
including lipopolysaccharide (LPS)-induced depression. In this study we tested the ability of IGF-I and GPE (the N-
terminal tri-peptide derived from IGF-I) to alter depression-like behavior induced by intraperitoneal (i.p.)
administration of LPS in a preventive and curative manner. In the first case, IGF-I (1 μg) or GPE (5 μg) was
administered i.c.v. to CD-1 mice followed 30 min later by 330 μg/kg body weight i.p. LPS. In the second case, 830
μg/kg body weight LPS was given 24 h prior to either IGF-I or GPE. When administered i.p., LPS induced full-blown
sickness assessed as a loss of body weight, decrease in food intake and sickness behavior. None of these indices
were affected by IGF-I or GPE. LPS also induced depression-like behavior; assessed as an increased duration of
immobility in the tail suspension and forced swim tests. When administered before or after LPS, IGF-I and GPE
abrogated the LPS response; attenuating induction of depression-like behaviors and blocking preexistent
depression-like behaviors. Similar to previous work with IGF-I, GPE decreased brain expression of cytokines in
response to LPS although unlike IGF-I, GPE did not induce the expression of brain-derived neurotrophic factor
(BDNF). LPS induced expression of tryptophan dioxygenases, IDO1, IDO2 and TDO2, but expression of these
enzymes was not altered by GPE. Thus, both IGF-I and GPE elicit specific improvement in depression-like behavior
independent of sickness, an action that could be due to their anti-inflammatory properties.
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Background
There is accumulating evidence that depression may
develop in response to activation of the innate immune
system [1-3]. Exposure of volunteers to a low dose of
endotoxin induces depressed mood that correlated with
cytokine expression, independent of sickness behaviors
[4]. Recently, a low dose of endotoxin given to volun-
teers was for the first time shown to induce anhedonia,
one of the primary features (diagnostic = DSM IV) for
depression [5]. An increase in negative affect follows
typhoid vaccine injections and similar to endotoxin
exposure, these mood changes correlate with the induc-
tion of cytokine secretion [6]. Studies such as these pro-
vide a correlation between mood changes and
inflammation, but a direct cause-effect link between
activation of the innate immune system and mood
changes came with human cytokine immunotherapy.
Cancer immunotherapy and cytokine treatment for
hepatitis C viral infection induces symptoms of depres-
sion in a significant percentage of patients [7,8]. These
symptoms develop on a background of neurovegetative
symptoms that are very similar to inflammation-induced
sickness behavior [3]. Together with the Reichenberg
study [4] showing a dissociation between depression and
overt sickness, there is now strong evidence that depres-
sion does not fully overlap with sickness and that
depression may be caused by cytokines in the brain.
In a rodent preclinical model, activation of the
immune system reliably induces depression-like behavior
assessed by several criteria including decreased prefer-
ence for a sweetened (saccharin) solution over water, as
an index of anhedonia, decreased sexual behavior [9],
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over water, increased time of immobility during the
forced swim test (FST) [10] and increased time of
immobility during the tail suspension test (TST) [11].
LPS induces transient sickness with the changes in pre-
ference for a sweetened solution or immobility in the
FST and TST still being evident after the disappearance
of sickness; i.e. after locomotor activity, social explora-
tion of a novel juvenile, body weight or food intake have
normalized. These depression-like behaviors are
reversed by anti-depressants and importantly by minocy-
cline which attenuates LPS-induced expression of brain
cytokines [9,11-14]. In all of these studies, depression-
like behaviors continued after the acute immune
response that was induced by LPS and the minocycline
study clearly indicated that the cytokine response was
requisite for the development of depression-like beha-
viors. These types of studies support the human data
that inflammation is causative in the development or
maintenance of depressive disorders.
Until recently, IGF-I has not been evaluated for anti-
depression actions on a background of inflammation.
We showed that i.c.v. IGF-I did not affect the acute
sickness response that was induced by i.c.v. LPS. In
contrast, IGF-I tempered cytokine expression and
depression-like behavior [11]. In that study, IGF-I also
increased the central expression of BDNF, a neurotro-
phin with well-characterized anti-depressant activity.
For that work, gene expression was quantified in
cDNA prepared from the entire perfused brain of mice
[11,13]. Whether, the LPS or IGF-I responses were glo-
bal or localized with a specific brain region was not
examined. However, following a single LPS injection,
pro-inflammatory cytokines, IL-1b,T N F a and IL-6 are
all similarly elevated in the hippocampus and frontal
cortex of mice [15]. Following repeated LPS injections,
IL-1b is elevated in the frontal cortex, hippocampus
and striatum [16]. These studies suggest that LPS
induces a global inflammatory response within the
brain and justified our previous use of total brain
mRNA as the source for cDNA to quantify an immune
response following LPS. However, it is clear from stu-
dies with humans that the frontal cortex plays a
unique role in depression [17-20]. Similarly with
rodents, electrical stimulation of the frontal cortex eli-
cits hedonic vocalizations [21], whereas lesions reduce
play behavior [22]. The antidepressant effect of fluoxe-
tine on immobility in the TST was shown to correlate
with BDNF expression in the frontal cortex, but not in
the hippocampus [23] implicating a unique role for the
frontal cortex in depression-like behavior of mice.
Thus in the current study, expression of genes asso-
ciated with inflammation were quantified in the frontal
cortex of mice.
IGF-I is well recognized as a neuroprotective hormone
and paracrine growth factor displaying activities in a
variety of neuropathologies [24,25]. IGF-I is cleaved
within the brain to release an N-terminal tripeptide [26].
GPE, like IGF-I, is neuroprotective both in vivo and in
vitro [27]. Lower amounts of GPE provide protection
when given i.c.v. compared to i.p. suggesting a central
site of action; indeed GPE does not appear to act out-
side the nervous system. Thus GPE may represent a
centrally active IGF-derivative, separating it from the
global role of IGF-I. Importantly, purification of IGF-I
from brain yields IGF-I lacking the first 3 amino acids
[26,28,29] suggesting that GPE is naturally produced in
the brain. Indeed, GPE is found in the normal brain [30]
and a protease that releases GPE is found in brain
[31,32]. Protease inhibitors, that prevent the release of
GPE from IGF-I, block IGF-I inhibition of GNRH secre-
tion [33,34]. This later finding strongly suggests that
GPE mediates at least part of the central action of IGF-
I. These finding suggest that GPE is a natural product
of central IGF-I and has naturalistic neuroprotective
actions. A central function for GPE, outside of cell sur-
vival such as behavior modification, has not been
reported. The current study shows that like IGF-I its’
natural cleaved product, GPE, has behavior modifying
activity. In the present series of experiments, we show
that both IGF-I and GPE administered centrally are able
to prevent and cure depression-like behavior induced by
peripheral administration of LPS.
Methods
Animals
Male CD-1 mice, 7 to 8 weeks old, were purchased from
Charles River Laboratory International, Inc. (Wilming-
ton, MA). Mice were group housed in ventilated cages
under a 12:12 h reversed light:dark cycle (lights off at
10:00 h) for 2 weeks until surgery. Juvenile, 3 to 4 wk of
age, C57BL/6J mice were used as novel targets for tests
of social exploration. Food and water was provided ad
libitum. Animal care and procedures were conducted
with the approval of the University of Illinois’ Institu-
tional Animal Care and Use Committee.
Surgery
Mice were anesthetized with ketamine (100 mg/kg body
weight) and xylazine (10 mg/kg body weight). Pain was
attenuated using buprenorphine (0.05 mg/kg body
weight) given prior to surgery. Mice were secured in a
stereotaxic instrument (David Kopf Instruments,
Tujunga, CA). Stainless-steel guide cannulae (26-gauge,
Plastics One Inc., Roanoke, VA) were implanted above
the lateral ventricle; 0.6 mm posterior and 1.3 mm lat-
eral to the bregma. The guide cannulae extended 1.3
mm below the skull. Cannulae were secured with “cold
Park et al. Journal of Neuroinflammation 2011, 8:179
http://www.jneuroinflammation.com/content/8/1/179
Page 2 of 16cure” Teets denture mixture (Co-oral-lte Dental MFG
Co, Diamond springs, CA). Mice were individually
housed post-surgery in conventional cages with a 2-
week recovery period before treatment.
Treatments
Mice were handled for at least 5 days prior to transfer
to a room in the behavioral suite 2-3 days before treat-
ment. A white noise Marpac soundscreen was used to
minimize interference from external sounds while in the
behavior suite. Experimental mice were 11 to 12 weeks
of age at treatment. All treatments were administered at
the end of light phase. IGF-I (recombinant human, Gro-
Pep, Adelaide, Australia) was prepared at 1 μg/μl, GPE
was prepared at 5 μg/μl and LPS (serotype 0127:B8,
Sigma, St. Louis, MO) at 33 or 83 μg/ml. IGF-I, GPE or
1 μl PBS were administered, injection time approxi-
mately 1 min, through the guide cannula and into the
lateral cerebral ventricle using a 33-gauge stainless-steel
cannula. Therefore, the final dose of IGF-I was 1 μg,
w h i c hw eh a v ep r e v i o u s l ys h o w nt ob ea c t i v ei . c . v .[ 1 1 ] ,
and the final dose of GPE was 5 μg, which is within the
range tested i.c.v. for neuroprotection [35,36]. LPS was
administered i.p. at 10 ml/kg body weight for final doses
of 330 or 830 μg/kg body weight. We have previously
shown that the higher dose of LPS causes depression-
like behavior for at least 24 h assessed using either the
forced swim, tail suspension or sucrose preference tests,
while locomotor activity is expected to return to normal
[10]. The low dose of LPS was determined empirically
as a dose that elicits depressive-like behavior after a
short acute-phase sickness response. At 330 μg/kg LPS
body weight, mice do not present with either sickness
or depression-like behaviors at 24 h (data not shown).
IGF-I, GPE or PBS were administered either 30 min
prior to 330 μg/kg LPS or PBS or they were adminis-
tered 24 h after 830 μg/kg LPS. Treatment combinations
are: PBS/PBS (Control), IGF-I or GPE/PBS (IGF-I or
GPE), PBS/LPS (LPS) and IGF-I or GPE/LPS (IGF-I +
LPS or GPE + LPS). LPS, at 830 μg/kg body weight,
induces depression-like behavior that lasts at least 30 h.
This time interval presents ample opportunity for IGF-I/
GPE administration to be given post- LPS (at 24 h)
while still permitting assessment of depression-like
behavior. LPS, at 330 μg/kg body weight induces a less
intense and more transient sickness response permitting
the evaluation of an IGF-I/GPE effect on the develop-
ment of depression-like behavior.
Sickness response
Body weight and food weight were recorded before
treatment and at various intervals post treatment. Sick-
ness associated with LPS administration parallels a loss
of body weight and decreased food intake. Social
exploration of novel C57BL/6J juvenile mice and general
locomotor activity were used to assess sickness behavior.
Social investigation was performed with protected juve-
niles; juveniles confined to a 8 × 8 × 11.5 cm wire cage
and placed in the corner of the experimental mouse’s
home cage [11]. Time spent by the experimental mouse
exploring the caged juvenile during the 5 min test inter-
val was recorded by a trained person blind to treatment.
Social exploration was performed 24 h prior to treat-
ment (baseline), then 2 and 6 h after treatment, using a
different juvenile at each time point. Social exploration
was used to assess recovery rate during the acute phase
of sickness; 2-6 h after LPS administration because it
can be administered repeatedly without habituation by
the test subject. Locomotor activity (LMA) was recorded
by a trained person blind to treatment from 5 min
recording of mice placed in a clean cage and was only
performed once for each experimental mouse 27 h after
treatment with LPS. We use this test to determine the
degree of residual sickness behavior when testing for
depression-like behavior at a single time point usually
24 to 30 h following LPS. This test was used in lieu of
social exploration because of its simplicity. LMA cannot
be used to assess rate of recovery during the acute
phase of sickness as it can only be performed once per
mouse, due to habituation. LMA was assessed as the
number of cage quadrants entered during the test per-
iod. All behavioral assessments were performed under
red light illumination during the dark phase of the light
cycle.
Depression-like behavior
Depression-like behavior was measured as duration of
immobility in the FST or TST and preference for con-
sumption of a sweetened solution (sucrose preference).
The TST was performed as previously described [11]
using the Mouse Tail Suspension Package (MED-TSS-
MS; Med Associates, St Albans, VT) 9 h after treatment
with LPS. Adhesive tape was attached to each mouse’s
tail for suspension from a strain gauge. Force from the
mouse’s struggle was recorded during a 10 min session.
Mice were considered immobile when force was below
the lower threshold. The FST was performed as pre-
viously described [13] 30 h after treatment with LPS.
Mice were recorded for 6 min and immobility recorded
by a trained person blind to treatment. Sucrose prefer-
ence was performed by quantifying disappearance of
liquid (change in weight) from bottles containing either
water or water containing 1% sucrose (wt./vol.). Prefer-
ence was calculated as disappearance of the sucrose
solution/disappearance of total fluid (water + sucrose).
Four hour sucrose preference was measured from 12
noon to 4 pm. Animals were trained for 3 days prior to
treatment; then preference was assessed on the same
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lowing day (4 h post-treatment with GPE).
Tissue preparation for real time PCR
Immediately after assessment of behavior, mice were
euthanized with CO2 then they were transcardially per-
fused with cold PBS. Brains were excised, dissected and
frozen on dry ice. The frontal cortex, containing the
frontal association, dorsolateral orbital, ventral orbital
and prelimbic cortices (first 1 mm of the frontal cortex
as defined in The Mouse Brain [37]), was collected and
stored at -80°C until solubilized with TRIzol (Invitrogen
Life Technologies, Carlsbad, CA) and RNA prepared as
d e s c r i b e d[ 1 1 ] .R N Aw a sq u a n t i f i e du s i n gaN a n o d r o p
ND-1000 spectrophotometer (Nanodrop Technologies,
Inc. Wilmington, DE). RNA was reverse transcribed
using High Capacity cDNA Reverse Transcription Kits
(catalog no. 4368813, Applied Biosystems, Foster city,
CA) to prepare cDNA. Real-time rtPCR was performed
to quantify steady-state mRNA as described previously
[11]. Assays were purchased from Applied Biosystems
(Foster City, CA) and amplification performed with a
Prism 7900 (Applied Biosystems) and the TaqMan uni-
versal PCR master mix (Applied Biosystems, catalog no.
4305719). A 50 ng aliquot of cDNA was used per reac-
tion. GAPDH was used to normalize target gene expres-
sion. Expression of GAPDH was not affected by any of
the treatment combinations (data not shown). Changes
in gene expression are expressed as 2
-ΔΔCts, where Ct is
the cycle threshold. A brief description of the target
genes and primers has been presented [11].
Statistical analysis
All data were expressed as mean ± SEM; Data were ana-
lyzed by a two-way (IGF-I × LPS) ANOVA using Stat-
View (SAS Institute Inc., San Francisco, CA) or
SigmaPlot (Systat Software, Inc., San Jose, CA). Where
appropriate (social investigation, changes in body weight
and food intake), data were analyzed using repeated
measures ANOVA. SigmaPlot was used for the prepara-
tion of figures. Tukey’s HSD (Honestly Significant Dif-
ference) was used for post hoc analysis when a
significant interaction was present.
Results
IGF-I does not prevent LPS-induced sickness, but
attenuates depression-like behavior
To assess its ability to prevent LPS-induced depression-
like behavior, IGF-I was administered i.c.v. 30 min prior
to LPS and several assessments were made to quantify
sickness and depression-like responses. To investigate
the effect of i.c.v. IGF-I on sickness, changes in body
weight, food intake and social exploration towards a
novel juvenile were assessed (Figure 1). As expected,
LPS administration at 330 μg/kg body weight i.p. caused
sickness, p < 0.05 evident by all measures. Mice treated
with LPS lost body weight (Figure 1A), ate less food
(Figure 1B) and spent less time exploring a novel juve-
nile mouse (Figure 1C). Mice were recovering between 6
and 9 h post-LPS for all three indices, although less-so
for food intake. These are typical responses for this low
dose of LPS. Administration of IGF-I i.c.v. did not alter
the ability of LPS to induce sickness, being without
effect on body weight, food intake and social explora-
tions, p > 0.05. Depression-like behavior was assessed by
duration of immobility during the tail suspension test
(Figure 1D). Duration of immobility was increased by
LPS (p < 0.05) and decreased by IGF-I (p < 0.05). The
interaction between the two treatments was significant
[F (1,80) = 4.9, p < 0.05]. Post-hoc analysis revealed that
duration of immobility did not differ between controls
and mice treated with IGF-I, although time spent immo-
bile by mice treated with IGF-I + LPS was still above
that of controls or IGF-I, p < 0.05; thus IGF-I did not
completely block LPS-induced depression-like behavior.
Duration of immobility was highest in mice treated with
LPS and was significantly different from that of all other
g r o u p s ,p<0 . 0 5 .T h u s ,s i m i l a rt oo u rp r e v i o u sw o r k
administering both IGF-I and LPS i.c.v. [11], i.c.v. IGF-I
has anti-depression like activity, but not anti-sickness
activity against i.p. administered LPS.
IGF-I does not affect preexisting LPS-induced sickness,
but alleviates LPS-induced depression-like behavior
To assess its ability to cure LPS-induced depression-like
behavior, IGF-I was administered i.c.v. 24 h after i.p.
LPS (when sickness behavior was expected to be mild or
absent; thereby testing for an antidepressant activity of
IGF-I following acute sickness). As in the prevention
model, several assessments were made to quantify sick-
ness and depression-like responses. As expected, LPS
administration at 830 μg/kg body weight i.p. caused
sickness, p < 0.05 evident by all measures. Mice treated
with LPS lost body weight (Figure 2A), ate less food
(Figure 2B). At 27 h, LPS-treated mice still had residual
albeit mild sickness evident as lower spontaneous move-
ment in a clean cage compared to controls: locomotor
activity (Figure 2C). These are typical responses for this
higher dose of LPS. Administration of IGF-I i.c.v. did
not alleviate the changes induced by LPS during the 6 h
time interval (24-30 h); IGF-I being without effect on
body weight, food intake and locomotor activity, p >
0.05. Depression-like behavior was assessed by duration
of immobility during the forced swim test (Figure 2D).
Duration of immobility was elevated by LPS and this
elevation in depression-like behavior was reversed by
IGF-I with a significant interaction between the two
treatments [F (1,21) = 5.5, p < 0.05]. Post-hoc analysis
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mice treated with IGF-I, or mice treated with both IGF-
I + LPS, p > 0.05. In contrast, immobility was highest in
mice treated with LPS and was significantly different
from all other groups, p < 0.05. Again, IGF-I had anti-
depression, but not anti-sickness activity.
GPE does not prevent LPS-induced sickness, but
attenuates depression-like behavior
To assess its ability to prevent LPS-induced depression-
like behavior, GPE was administered i.c.v. 30 min prior
to LPS to quantify sickness and depression-like
responses. LPS administration i.p. caused sickness again
evident by all measures, p < 0.05: mice treated with LPS
lost body weight (Figure 3A), ate less food (Figure 3B)
and spent less time exploring a novel juvenile mouse
(Figure 3C). Mice recovered between 6 and 9 h post-
LPS for all three indices. Administration of GPE i.c.v.
did not alter the ability of LPS to induce sickness, being
without effect on body weight, food intake and social
explorations, p > 0.05. Depression-like behavior was
assessed by duration of immobility during the tail sus-
pension test (Figure 3D). Immobility was elevated by
LPS (p < 0.05) and reduced by GPE (p < 0.05) although
the interaction between the two treatments did not
reach significance. These changes show that GPE has
Figure 1 IGF-I does not affect sickness, but prevents the development of depression-like behavior induced by LPS. Mice were treated
with vehicle or IGF-I (1 μg i.c.v.) followed 30 min later by vehicle or LPS (330 μg/kg body weight i.p.). Sickness was assessed as changes in body
weight (A) and food intake (B), while sickness behavior was assessed as change in time spent investigating a novel juvenile (C). Depression-like
behavior was quantified as the time of immobility during the FST, 9 h after treatment with LPS (D). n = 17-21 per treatment.
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activity.
GPE does not affect preexisting LPS-induced sickness, but
alleviates LPS-induced depression-like behavior
To assess its ability to cure LPS-induced depression-like
behavior, GPE was administered i.c.v. 24 h after i.p. LPS.
As described above, LPS administration at 830 μg/kg
b o d yw e i g h ti . p .c a u s e ds i c k n e s s ,p<0 . 0 5e v i d e n tb ya l l
measures: mice treated with LPS lost body weight (Fig-
ure 4A), ate less food (Figure 4B) and had lower sponta-
neous movement in a novel clean cage: locomotor
activity (Figure 4C). Administration of GPE i.c.v. did not
alleviate the changes induced by LPS; GPE being with-
out effect on body weight or food intake during the 6 h
time interval (24-30 h). GPE decreased locomotor activ-
ity, p < 0.05; without a significant LPS × GPE interac-
tion, p > 0.05. Depression-like behavior was assessed by
duration of immobility during the FST (Figure 4D).
Duration of immobility was elevated by LPS. GPE had
no effect on its own, on the duration of immobility dur-
ing the FST, but there was a significant interaction
between the effects of LPS and GPE [F (1,19) = 8.5, p <
0.05]. Post-hoc analysis revealed that immobility did not
differ between controls, mice treated with GPE, or mice
t r e a t e dw i t hb o t hG P E+L P S ,p>0 . 0 5 .I nc o n t r a s t ,
Figure 2 IGF-I does not affect sickness, but relieves depression-like behavior induced by LPS. Mice were treated with vehicle or LPS (830
μg/kg body weight i.p.) followed 24 h later by vehicle or IGF-I (1 μg i.c.v.). Sickness was assessed as changes in body weight (A) and food intake
(B) while sickness behavior was assessed as change in general activity, 27 h after treatment with LPS (C). Depression-like behavior was quantified
as the time of immobility during the FST, 30 h after treatment with LPS (D). n = 6.
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LPS and significantly different from controls or mice
treated with GPE plus LPS, p < 0.05. Again, GPE had
anti-depression activity. In contrast to these findings,
GPE was unable to reverse the decrease in sucrose pre-
ference observed following LPS administration. As shown
in Figure 4E, sucrose preference was stable for the two
days prior to treatment for all treatment groups. LPS
caused a decrease in sucrose preference during the 4 to 8
h interval after treatment. Sucrose preference was still
depressed for LPS-treated mice when assessed 28 to 32 h
after treatment. GPE, given 24 h after LPS, did not alter
sucrose preference 4 to 8 h later (28 to 32 h post-LPS).
GPE administered i.c.v. decreases i.p. LPS-induced
expression of brain cytokines
LPS-induced changes in behavior are dependent on the
induction of brain pro-inflammatory cytokines. We had
previously shown that IGF-I diminishes expression of
brain cytokines [11]; a possible mechanism to alleviate
depression-like activity. Thus the ability of GPE to alter
the expression of inflammatory factors within the frontal
cortex was examined. LPS (Figure 5) significantly (p <
0.05) increased mRNA expression of IL-1b and TNFa
(Figure 5A and 5B, respectively). In both cases, GPE
alone did not affect basal cytokine expression (p > 0.05),
but significantly attenuated the LPS induction of TNFa
Figure 3 GPE does not affect sickness, but prevents the development of depression-like behavior induced by LPS.M i c ew e r et r e a t e d
with vehicle or GPE (5 μg i.c.v.) followed 30 min later by vehicle or LPS (330 μg/kg body weight i.p.). Sickness was assessed as changes in body
weight (A) and food intake (B), while sickness behavior was assessed as change in time spent investigating a novel juvenile (C). Depression-like
behavior was quantified as the time of immobility during the FST, 9 h after treatment with LPS (D). n = 7-8.
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μg/kg body weight i.p.) followed 24 h later by vehicle or GPE (5 μg i.c.v.). Sickness was assessed as changes in body weight (A) and food intake
(B) while sickness behavior was assessed as change in general activity, 27 h after treatment with LPS (C). Depression-like behavior was quantified
as the time of immobility during the FST, 30 h after treatment with LPS, or sucrose preference (D). n = 5-6.
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followed 30 min later by vehicle or LPS (330 μg/kg body weight i.p.). Mice were sacrificed, perfused and brains collected 9 h later. Steady-state
mRNA expression of pro-inflammatory markers, IL-1b (A), TNFa (B), YM-1 (C) and iNOS (D), was quantified by real-time rtPCR in the prefrontal
cortex and expressed relative to GAPDH. GAPDH expression was constant across treatment, p > 0.5, and changes in gene expression shown in
Figures 5, 6, and 7 reflect treatment-induced effects on target gene expression. n = 11-12.
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0.05]) and approached significance for IL-1 b (interac-
tion between LPS and GPE [F (2,42) = 3.7, p = 0.06]).
Expression of YM-1, a marker of microglia activation
[38], was also elevated by LPS (Figure 5C). Similar to
TNFa, there was an interaction between LPS and GPE
for YM-1 expression [F (2,42) = 5.5, p < 0.05]. Post-hoc
analysis indicated that GPE attenuated LPS induction of
YM-1. LPS increased iNOS expression (p < 0.05).
Although GPE appeared to reduce expression of iNOS,
the effect of GPE and its interaction with LPS was not
significant (Figure 5D). IL-10 expression was induced by
LPS and attenuated by GPE with a significant interac-
tion between LPS and GPE [F (2,42) = 8.6, p < 0.05].
Post-hoc analysis indicated that GPE did not return the
level of IL-10 expression to that of controls, but there
was no significant difference between expression in mice
treated with GPE or LPS + GPE (Figure 5E) Overall,
these data indicate that glial activation is suppressed by
central GPE, offsetting the inflammatory response
initiated by i.p. LPS.
GPE administration does not regulate expression of
tryptophan dioxygenases
To assess the possible involvement of changes in trypto-
phan metabolism in LPS-induced depression-like beha-
vior and GPE’s antagonistic actions, expression of IDO1,
IDO2 and TDO2 were quantified in the frontal cortex.
Assays designed to probe for expression of IDO1’sf u l l -
size transcript (probe spanning exons 1 and 2) and one
that quantified all transcripts (probe spanning exons 3
and 4) used to quantify IDO1 expression. Expression of
IDO1 ex. 1-2 was increased almost 300-fold by LPS, p <
0.05, but unaffected by GPE (Figure 6A). Expression
IDO1 ex. 3-4 amplification was increased by LPS to
~2.5-fold of controls, p < 0.05, but expression again was
unaffected by GPE (Figure 6B). IDO2 and TDO2 expres-
sion were quantified with probes that span exons 3 and
4 and 4 to 5, respectively. These assays quantify all tran-
scripts. Expression of IDO2 (Figure 6C) and TDO2 (Fig-
ure 6D) were both increased by LPS, p < 0.05, but
unaffected by GPE. These data indicate that GPE is not
altering depression-like behavior by reducing the LPS-
induction of tryptophan dioxygenase mRNA expression.
GPE administration does not regulate expression of either
IGF-I or BDNF
To assess the possible involvement of changes in neuro-
trophin expression in the GPE behavior response,
expression of IGF-I, VEGF and BDNF were quantified.
IGF-IEb was decreased by LPS, p < 0.05, but unaffected
by GPE (Figure 7A). VEGF was also decreased by LPS, p
< 0.05, but again GPE had not effect (Figure 7B). BDNF
is synthesized from multiple transcripts within the brain.
LPS decreased the expression of both of the transcripts
that were measured, BDNF exon I-IX (Figure 7C) and
BDNF exon VI-IX (Figure 7D). Neither mRNA tran-
script for BDNF was affected by GPE. Thus, although
LPS clearly decreases neurotrophin expression, GPE
does not reverse this action.
Discussion
Three new findings are evident from the current studies,
1) although they both share an inflammatory compo-
nent, sickness and depression-like behavior are indepen-
dently modulated by the IGF system, 2) when added
exogenously, two naturally occurring products found in
the naïve brain, mature IGF-I and GPE, act centrally to
temper LPS-induced changes in depression-like beha-
vior, and 3) GPE can temper the central innate immune
response to LPS providing a possible mechanism by
which to regulate depression-like behavior. A direct
behavior modifying role of GPE has never been
reported. Previous studies with the GPE peptide had
shown biological activity associated with neuroprotec-
tion using preclinical models for Alzheimer’s, Parkin-
son’s disease, stroke, multiple sclerosis and Huntington’s
[27], but a central behavioral effect that is independent
of neuroprotection had yet to be reported. Neither IGF-
I or GPE affected behavior of naïve (non-LPS) mice, but
had anti-depressant activity when tested against the
inflammation-inducer LPS in the TST and FST. It’sn o t
known whether the effect of GPE can be extended to
other models of depression as GPE was not able to
reverse LPS-induced decrease in sucrose preference,
used as an index of anhedonia.
Other studies have shown that IGF-I has anti-depres-
sant activity using various rodents models. Voluntary
exercise increases blood and brain IGF-I levels. This
increase is in part responsible for exercise-induced anti-
depressant activity [39]. An anti-IGF-I antibody blocked
the decreased time of immobility during the FST of
exercised mice [40], indicating that exercise-induced
increases in IGF-I has a naturalistic and endogenous
role in controlling behavior. Similarly, rough-and-tumble
play of rats increases IGF-I levels in the frontal and par-
ietal cortex and also increases hedonic 50-kHz ultraso-
nic vocalizations [41]. The play-induced increase in
hedonic vocalizations was dependent on IGF-1R activa-
tion and i.c.v. administration of IGF-I increased hedonic
vocalizations and decreased approach latency to self-
administered play. IGF-I also decreased time of immobi-
lity in the FST, decreased consumption latencies in the
novelty-induced hypophagia test using naïve mice and
increased sucrose consumption of mice subjected to
chronic unpredictable stress [40,42-44]. Activating endo-
genous IGF-I, by freeing it from inhibitory IGF-binding
proteins with NBI-31772, decreased immobility in the
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by JB1, an IGF-1R antagonist [44] supporting a mechan-
ism that requires activation of IGF-1R. A single i.c.v.
injection of IGF-I to rats decreased immobility during
the FST [42] while JB1 blocked the anti-depressant
activity of IGF-I [43]. Data such as these, especially with
naïve animals, show that the behavior modifying role of
endogenous and exogenous IGF-I is independent of
IGF-I’s well documented neuroprotective actions and
that the anti-depressant activity of IGF-I can be quanti-
fied with several tests that have proven to be reliable
indices of depression-like behaviors. Blocking the anti-
depressant activity of exogenous IGF-I with JB1, which
prevents IGF-1R receptor activation, shows that IGF-1R
activation is requisite for IGF-I action, but does not
show whether all the effects are mediated by the IGF-
1R. With this in mind we determined whether the nat-
uralistic product of IGF-I cleavage within the brain that
acts independent of the IGF-1R [45] can exert additional
anti-depressant activity.
In the current study, GPE had very similar actions
compared to IGF-I. GPE, given before or after LPS, eli-
cited an anti-depressant effect with mice using either
the TST or FST. Like IGF-I, GPE did not alter the sick-
ness response to i.p. LPS. The lack of an effect of these
peptides on sickness is not unexpected. LPS given i.p.
elicits a strong peripheral immune response and also
sends inflammatory-initiating signals to the brain via the
vagus nerves and other immune-to-brain communica-
tion pathways [46]. The acute peripheral immune
Figure 6 LPS increases the expression of tryptophan dioxygenases, but GPE does not attenuate this response. Mice were treated as in
Figure 5. Steady-state mRNA expression, of three enzymes that metabolize tryptophan to kynurenine, IDO1 (A, B), IDO2 (C) and TDO2 (D), was
quantified by real-time rtPCR in the prefrontal cortex and expressed relative to GAPDH. n = 11-12.
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via the humoral and neural communication pathways is
unlikely to be altered by i.c.v. administration of either
IGF-I or GPE. Thus in this model, the sickness response
appears to be largely under the control of the peripheral
inflammatory input to the brain. These primary signals
subsequently initiate an activation of the innate immune
system of the brain which is tempered by GPE (Figure
5). Decreased neuroinflammation in response to IGF-I
[11] and GPE (current study) correlate with changes in
depression-like behavior when assessed using the TST
and FST. The anti-depressant activities of IGF-I and
GPE in the current experiments assessed with the TST
and FST does not appear to be a result of an overall
attenuation of psychomotor retardation as locomotor
activity was unaffected by either IGF-I or GPE. GPE was
unable to alter mouse performance in a test for anhedo-
nia. Sucrose preference was not affected by GPE.
Attempts to assess the activity of IGF-I on sucrose pre-
ference were complicated by the ability of an acute IGF-
I challenge to enhance sucrose consumption in naïve
mice (data not shown), reflecting its insulin-like activity
and ability to directly alter glucose metabolism. Differ-
ential effects with the TST and FST versus sucrose pre-
ference suggest that GPE plays a specific role in
alleviating only some symptoms of inflammation-
induced depression, helplessness/despair, without affect-
ing another, anhedonia. An hedonic response may
require mature IGF-I or chronic exposure. In a study by
Duman, chronic subcutaneous infusion of IGF-I (~1-1.5
Figure 7 LPS depresses the expression of neurotrophic factors, but GPE does not alter the LPS response. Mice were treated as in Figure
5. Steady-state mRNA expression of several neurotrophic factors, IGF-I (A), VEGF (B) and BDNF (C, D), was quantified by real-time rtPCR in the
prefrontal cortex and expressed relative to GAPDH. n = 11-12.
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Page 12 of 16mg/day for 14 d, vs. a 1 mg bolus in the current work)
did not increase sucrose consumption in naïve mice (an
effect we have found with bolus IGF-I injection i.c.v.),
but this constant chronic infusion of IGF-I reversed the
lowered sucrose consumption by mice subjected to
chronic unpredictable stress [40]. Our new finding how-
ever provides a novel model to help define central path-
ways controlling specific behavioral symptoms.
We previously found that IGF-I induced the expres-
sion of several BDNF transcripts [11]; another possible
mediator of its anti-depressant activity. One of the more
interesting aspects of BDNF biology is the differential
expression and regulation of specific transcripts. All
transcripts produce mature BDNF, but in different cells
types. Transcripts initiating from exons I, II and III are
expressed predominantly in neurons and transcripts
initiating from exons IV, V and VI are expressed by
both neurons and astrocytes [47]. Normal expression of
all transcripts may be necessary for wellness, as a knock-
out of even a single transcripts causes depression-like
behavior of mice [48]. Duloxetine, an SNRI class anti-
depressant, increases the expression of only 4 of the 9
transcripts [49] indicating specificity of treatment. Thus
we again examined multiple BDNF transcripts. However,
GPE did not induce BDNF expression and thus BDNF
may not play a significant role in the anti-depressant
role of GPE. Only a single dose of GPE was tested in
t h ep r e s e n ts t u d y ;ad o s ew i t h proven neuroprotective
action [35,36]. The present results call for a more exten-
sive investigation of the dose-response effect of GPE on
inflammation-induced depression and moreover on the
ability of endogenously generated GPE to mediate part
of the anti-depressant activity of IGF-I.
Clearly from studies mentioned above, the anti-
depressant activity of mature IGF-I is dependent of IGF-
1R signaling, which also mediates IGF-I’sn e u r o p r o t e c -
tive action. The receptor that mediates GPE action on
behavior has not been characterized. GPE was shown to
displace glutamate from its receptor, but GPE’sn e u r o -
protective activity is not clearly related to glutamate/
NMDA receptor (NMDA-R) binding as it competes
with glutamate binding with a very low affinity (30 μM)
even though neuroprotective activity is evident at 0.1
nM [33,34,45,50,51]. This discrepancy suggests that GPE
activity is dependent on an as yet uncharacterized
mechanism [52]. Peptidase inhibitors that block proces-
sing of many proteins including the release of GPE from
intact mature IGF-I with the generation of des-(1-3)-
IGF-I, block IGF-I inhibition of GNRH secretion [33,34]
suggesting that GPE mediates at least part of the central
action of IGF-I. Mature intact IGF-I has antidepressant
activity, but it is still not known if des-(1-3)-IGF-I, act-
ing via the IGF-1R, or the generation of GPE from exo-
genous IGF-I play a significant role in the
antidepressant activity of the intact mature peptide.
H o w e v e r ,s i n c eb l o c k a g eo fI GF-1R activity abrogates
anti-depressant activity of the mature peptide [44] and
GPE does not activate the IGF-1R [45], clearly IGF-I
itself has anti-depressant activity through the IGF-1R
independent of GPE. Thus it appears that IGF-I has the
potential to generate two distinct signaling events that
result in anti-depressant activity; an IGF-1R mediated
action and an IGF-1R independent GPE-mediated
action.
One common link between IGF-I and GPE that may
be related to their anti-depressant activity is their com-
mon ability to attenuate the activity of quinolinic acid
[53,54]. Induction of tryptophan dioxygenase activity by
inflammation plays a major role in depression as shunt-
ing of tryptophan metabolism toward the generation of
metabolites such as quinolinic acid has been linked to
inflammation-associated depression [55]. Using mice as
a preclinical model, i.p. LPS induces IDO1 activity in
the periphery and brain [56] with an increase in central
and plasma kynurenine/tryptophan ratios [13]. Increased
IDO1 expression is associated with the generation of
kynurenine metabolites (kynurenic acid, 3-hydroxyky-
nurenine and quinolinic acid) that are active neuromo-
dulators. Increased levels of these modulators are
associated with inflammation-dependent depression
[57]. It is not clear as to which of these metabolites
have a causative role in depression or if periphery or
brain-generated tryptophan metabolites are responsible
for depression-like behaviors but induction of peripheral
or central IDO1 expression correlates with depression-
like behavior of mice. IDO1 expression was quantified
using two qPCR assays. IDO1 protein is translated from
multiple transcripts with the full length transcript being
less widely distributed in the body than other transcripts
[58]. Although not reported for brain samples, in the
placenta the major transcript does not include much of
exon 1 [59]. An assay designed to probe for expression
of IDO1’s full-size transcript (probe spanning exons 1
and 2) resulted in weak amplification in controls (Ct =
38.7). Expression of all major IDO1 variants was quanti-
fied using a probe that spans exons 3 and 4. IDO1 ex.
3-4 amplification is much stronger in control brain sam-
ples, Ct = 27.4, than that of IDO1 ex. 1-2. IDO2 and
TDO2 expression were quantified with probes that span
exons 3 and 4 and 4 to 5, respectively. These assays
quantify all major transcripts. Amplification of IDO2 in
control mice was slightly stronger than that for IDO1
ex. 3-4 with a Ct value of 24.4, whereas amplification of
TDO2 was weaker, Ct = 30.5. Although Ct values do
not imply differences in mRNA levels within samples,
because of probable differences in assay-to-assay qPCR
efficiencies, the extremely low Ct value for IDO1 ex. 1-2
compared to all other dioxygenases indicate that in
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translation. However, expression of IDO1 ex. 1-2 may
play an important role in neurophysiology because of its
strong induction with neuroinflammation; in this case
following administration of LPS. In our current model,
IDO1, IDO2 AND TDO2 mRNA expression, which are
rate-limiting enzymes for the conversion of intracellular
tryptophan to kynurenine, were all increased by LPS.
Expressions were unaffected by GPE; similarly IGF-I did
not attenuate LPS-induced dioxygenase expression
(unpublished data). These data seem to suggest that
IGF-I and GPE do not act by altering the consequences
associated with elevated dioxygenase expression. How-
ever, it remains to be determined if IGF-I or GPE alter
the effects of elevated tryptophan dioxygenase expres-
sion downstream of the enzyme; i.e. by directly attenuat-
ing the activity of quinolinic acid or other downstream
products such as 3’-hydroxykynurenine or kynurenic
acid.
Cytokine and neurotrophin mRNA expression was
quantified in the prefrontal cortex as this region has
been strongly implicated in the regulation of positive
affect. In rodents, electrical stimulation of the frontal
cortex elicits hedonic vocalizations by rodents, [21],
whereas lesions reduce rough-and-tumble play behavior
[22] both associated with a positive emotional state.
Although many studies show a strong correlation
between changes in the frontal cortex and hippocampus,
the antidepressant effect of fluoxetine was shown to cor-
relate with BDNF expression in the frontal cortex, but
not in the hippocampus [23]. With humans, several
positive affective stimuli increase neuronal activity in
the frontal cortex [17-20]. Here we show that LPS
induces expression of central cytokine and GPE reduces
their expression in a brain region intimately associated
with depression-like behaviors. The opposing effects of
LPS and GPE on cytokine expression parallel changes in
depression-like behavior.
The neurotrophic hypothesis for depression asserts
that neuronal plasticity is dysfunctional because of insuf-
ficient neurotrophic support and that classic anti-
depressants ultimately reactivate plasticity in the brain
[60-62]. IGF-I is a classic neurotrophin; inducing the
proliferation, survival, differentiation and maturation of
cells of the central nervous system [63] and directly sup-
porting neuronal plasticity [64]. GPE is also a neurotro-
phin; although characterized primarily by its ability to
support neuronal survival and stimulation of glia prolif-
eration [65]. IGF-I is expressed by neurons within the
brain [66-68] and expression was reduced by the admin-
istration of LPS (Figure 7). This reduction would trans-
late into low central levels of both IGF-I and GPE
within the frontal cortex. This reduced protein expres-
sion would result in lower neurotrophic support along
with the lower expression of BDNF and VEGF (Figure
7). By administration of IGF-I or GPE neurotrophic sup-
port is exogenously provided and depression-like beha-
vior is attenuated.
In conclusion, data in this manuscript show that exo-
genous central administration of either IGF-I or GPE
results in anti-depressant-like activity, assessed using the
TST and FST. The behavioral changes did not occur
with naïve mice but these neurotrophins attenuated the
behavioral changes induced by i.p. LPS. These data
extend the anti-depressant activity of the IGF system by
showing that a proteolytic product derived from IGF-I,
GPE, has anti-depressant activity paralleling that of the
mature peptide. Both IGF-I and GPE offset the inflam-
matory response elicited by LPS which may in part be
responsible for anti-depressant activity.
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